Contraline, Inc., a clinical-stage biopharmaceutical company, has secured $92.5 million in a Series B financing round to advance its novel male contraceptive pipeline. The funding was co-led by BVF Partners L.P. and RA Capital Management, with participation from GV and other key investors. These proceeds will primarily support the late-stage development of NES/T Gel, an investigational daily hormonal contraceptive for men.
Pioneering a New Male Contraceptive
The focus of the new capital is NES/T Gel, a potential first-in-class, reversible male contraceptive designed for daily application. This topical gel combines segesterone acetate with testosterone to suppress sperm production while maintaining healthy hormone levels. Its development marks a significant step toward providing men with a non-invasive, hormonal family planning option.
NES/T has already shown considerable promise, having recently completed a global Phase 2b trial involving 462 couples. The study demonstrated encouraging results for the gel's efficacy, tolerability, and user acceptability. Importantly, the contraceptive effect was shown to be reversible, a key feature for users considering family planning.
Addressing a Major Unmet Need
The development of a reliable male contraceptive addresses a significant gap in modern reproductive health. According to CEO Kevin Eisenfrats, Contraline aims to expand reproductive choice for men and couples globally. Survey data highlights this demand, suggesting over 40 million men in the U.S. would consider using such a product.
This innovation could fundamentally shift family planning dynamics by empowering men with more control and options. It offers an alternative for couples where existing female-centric methods are not ideal. The introduction of a male-controlled contraceptive fosters shared responsibility in reproductive decisions.
Investor Confidence and Strategic Vision
The successful financing reflects strong investor confidence in Contraline's vision and the scientific merit of its programs. The round was co-led by prominent life sciences investors and included participation from GV (Google Ventures). As part of the deal, Iris van Alderwerelt van Rosenburgh of BVF Partners will join Contraline’s Board of Directors.
Investor representatives voiced their excitement for the company's potential to redefine a long-overlooked area of healthcare. They believe this is a meaningful step towards expanding contraceptive options for couples worldwide. This new chapter in reproductive health gives men a more active role in family planning.
Broader Pipeline and Development
The NES/T program was originally developed by the Population Council in collaboration with the NICHD. Contraline now holds the exclusive worldwide rights to develop and commercialize this promising asset. The company plans to initiate a pivotal Phase 3 clinical trial for NES/T in 2027.
In addition to NES/T, Contraline is advancing other male contraceptive technologies to build a diverse portfolio. The company is also developing ADAM™, an investigational, long-lasting, and non-hormonal contraceptive. This dual approach demonstrates a comprehensive commitment to innovating in male reproductive health.
This $92.5 million capital infusion is a landmark achievement for Contraline and a pivotal moment for the field of male contraception. The funding accelerates the development of NES/T Gel and reinforces the growing demand for new family planning solutions. As the program progresses, it holds the potential to transform reproductive health by providing a safe and effective option for men globally.